Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Ned Tijdschr Geneeskd. 2012;156(41):A5029.

[Discriminative ability, reclassification and net benefit: the predictive value of biomarkers].

[Article in Dutch]

Author information

  • 1Erasmus MC, afd. Maatschappelijke Gezondheidszorg, Rotterdam, the Netherlands. e.steyerberg@erasmusmc.nl


More and more biomarkers are becoming available to predict the risk of disease. Several performance measures are used to express the predictive value of a biomarker. In this article we use as an example the Framingham risk score with and without the HDL cholesterol concentration as a risk factor for the prediction of the occurrence of cardiovascular disease. We consider 3 performance measures for diagnostic or prognostic quality: (a) the area under the Receiver Operating Characteristic (ROC) curve (AUC), a traditional measure to indicate discriminative ability; (b) the Net Reclassification Improvement (NRI), a popular measure based on the improvements in the high- and low-risk classification of patients by adding the HDL value as a risk factor; (c) Net Benefit, a measure based on decision sciences. Net benefit is a better measure for the value of a biomarker, since it takes more of the clinical context into account and is easier to interpret than the AUC and the NRI.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bohn Stafleu van Loghum
    Loading ...
    Write to the Help Desk